<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351685</url>
  </required_header>
  <id_info>
    <org_study_id>VPM1002-MN-3.05TB</org_study_id>
    <nct_id>NCT04351685</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants</brief_title>
  <acronym>VPM1002</acronym>
  <official_title>A Multicenter, Phase III, Double-blind, Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Mycobacterium Tuberculosis Infection in Newborn Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Serum Institute of India Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vakzine Projekt Management GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Serum Institute of India Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is designed as a phase III, double-blind, multicenter, randomized, single
      administration, active-controlled, parallel-group design with two groups of newborn infants
      receiving either VPM1002 or BCG SII (1:1 allocation) to assess the efficacy, safety and
      immunogenicity of VPM1002 against Mtb infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is designed as a phase III, double-blind, multicenter, randomized, single
      administration, active-controlled, parallel-group design with two groups of newborn infants
      receiving either VPM1002 or BCG SII (1:1 allocation) to assess the efficacy, safety and
      immunogenicity of VPM1002 against Mtb infection.

      Healthy male or female newborn infants will be centrally randomized to receive the allocated
      vaccine, stratified by the HIV status of the mother. Single dose of VPM1002 or BCG SII will
      be administered (within 14 days of birth) strictly intradermally.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 10, 2020</start_date>
  <completion_date type="Anticipated">June 10, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The study is designed as a double-blind study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incident cases of QFT conversion, indicating Mtb infection</measure>
    <time_frame>Minimum of 12 months and maximum of 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of TB disease in children receiving VPM1002 compared to BCG SII. Incident cases of sustained QFT conversion, indicating sustained Mtb infection.</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6940</enrollment>
  <condition>Mycobacterium Tuberculosis Infection</condition>
  <arm_group>
    <arm_group_label>VPM1002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total 3470 subjects will be enrolled in VPM1002 arm.
Single dose of VPM1002 will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCG SII</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Total 3470 subjects will be enrolled in BCG SII arm.
Single dose of BCG SII will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VPM1002</intervention_name>
    <description>The active ingredient of the recombinant BCG vaccine, VPM1002 is Mycobacterium bovis A dose of 0.05 ml will be administered intradermally.
Manufactured by the Serum Institute of India Pvt. Ltd., India
Diluent: 1 ml of Water for injection/vial</description>
    <arm_group_label>VPM1002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG SII</intervention_name>
    <description>Commercially available BCG vaccine from Serum Institute of India Pvt. Ltd. A dose of 0.05 ml will be administered intradermally.
Manufactured by the Serum Institute of India Pvt. Ltd., India
Diluent: 1 ml of Sodium Chloride for injection/vial Injection</description>
    <arm_group_label>BCG SII</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A Maternal

          1. Age: 18 years or older at screening.

          2. Willing to comply with the trial protocol, available and willing to allow her child to
             complete all the trial assessments and must have signed an Informed Consent form that
             has been approved by respective Site Ethics Committee.

          3. No symptoms or signs of active TB at the time of participant's enrolment.

          4. Parent / guardian who intends to remain in the trial area with the child should be
             reachable by phone during the trial period.

        B Infant

          1. Healthy male or female newborn infant.

          2. Birth weight of at least 2,300 g.

          3. Test negative for HIV by PCR at screening if born to an HIV-infected mother.

          4. No participation in an interventional clinical trial prior to enrolment. Participant
             should not take part in another clinical trial for the duration of the current trial
             period.

        Exclusion Criteria:

        A Maternal

          1. Any reported or suspected substance abuse during pregnancy.

          2. House-hold contact with active TB (defined as residing in the same house as an
             individual with active TB) within the 3 months prior to enrolment.

        B Infant

          1. Fever at the time of enrolment.

          2. Eczema or other significant skin lesion or infection at the site/s of injection as per
             protocol.

          3. Receipt of routine BCG vaccine (as per vaccination record).

          4. Clinically suspected sepsis.

          5. Any malignant condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Prasad Kulkarni, MD</last_name>
    <role>Study Director</role>
    <affiliation>Serum Institute of India Pvt. Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr Prasad Kulkarni, MD</last_name>
    <phone>+ 91-20-26602384</phone>
    <email>drpsk@seruminstitute.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr Sajjad Desai, MD</last_name>
    <phone>+ 91-20-26602781</phone>
    <email>sajjad.desai@seruminstitute.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de Recherches Médicales de Lambaréné</name>
      <address>
        <city>Lambaréné</city>
        <country>Gabon</country>
      </address>
    </facility>
    <contact>
      <last_name>Prof Ayola Adegnika</last_name>
      <phone>+24106244472</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kenya Medical Research Institute / Center for Respiratory Disease Research</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr Videlis Nduba</last_name>
      <phone>+254724522474</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kenya Medical Research Institute - Center for Respiratory Disease Research</name>
      <address>
        <city>Siaya</city>
        <zip>144</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr Videlis Nduba</last_name>
      <phone>+254 724 522474</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Family Clinical Research Unit</name>
      <address>
        <city>Cape Town</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Prof Mark Frederic Cotton</last_name>
      <phone>+27219384963</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MeCRU clinical research Unit</name>
      <address>
        <city>Pretoria North</city>
        <zip>0204</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Matsontso Peter Mathebula</last_name>
      <phone>+270125215714</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Respiratory and Meningeal Pathogens Research Unit</name>
      <address>
        <city>Soweto</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Prof Shabir Ahmed Madhi, MD</last_name>
      <phone>+27119834283</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cape Town South African Tuberculosis Vaccine Initiative</name>
      <address>
        <city>Worcester</city>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr Angelique Kany Kany Luabeya</last_name>
      <phone>+27233465400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ifakara Health Institute</name>
      <address>
        <city>Dar Es Salaam</city>
        <zip>61665</zip>
        <country>Tanzania</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr Francis Mhimbira</last_name>
      <phone>+225754291657</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Research Council / Uganda Virus Research Institute and London School of Hygiene and Tropical Medicines (MRC/UVRI and LSHTM) Uganda Research Unit</name>
      <address>
        <city>Entebbe</city>
        <country>Uganda</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr Anne Wajja</last_name>
      <phone>+256778103960</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Makerere University/CISMAC</name>
      <address>
        <city>Kampala</city>
        <zip>7062</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr Victoria Nankabirwa</last_name>
      <phone>+256755757460</phone>
    </contact>
  </location>
  <location_countries>
    <country>Gabon</country>
    <country>Kenya</country>
    <country>South Africa</country>
    <country>Tanzania</country>
    <country>Uganda</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bacterial and fungal diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

